来氟米特对激素耐药型儿童紫癜性肾炎的临床疗效及安全性  

Exploring the clnical efficacy and safety of leflunomidein the treatment of steroid-resistant HSPN in children

作　　者：秦可佳 杨玲霞 崇华学 郝普来 QIN Kejia;YANG Lingxia;CHONG Huaxue;HAO Pulai(The First Hospital of Qiqihar City,Qiqihar 161005,China)

机构地区：[1]齐齐哈尔市第一医院儿科,黑龙江齐齐哈尔161005

出　　处：《黑龙江医药科学》2024年第5期26-28,共3页Heilongjiang Medicine and Pharmacy

基　　金：齐齐哈尔市科技计划创新激励项目,来氟米特治疗儿童紫癜性肾炎食物临床疗效及安全性研究,编号:CSFGG-2022103。

摘　　要：目的:探讨来氟米特在治疗激素耐药型儿童紫癜性肾炎(HSPN)中的效果及其安全性。方法:选取齐齐哈尔市第一医院2018年8月至2022年12月儿科收治的激素耐药型HSPN患儿69例,通过随机数字表法进行分组,分为试验组与对照组。试验组患儿接受激素联合来氟米特的治疗方案,而对照组则采用激素联合环磷酰胺的治疗方案。在治疗后的第6个月,分别对两组患儿进行临床疗效及药物副作用的评估。结果:在治疗前,两组患儿的24 h尿蛋白定量均值相近,无统计学差异(P>0.05)。在治疗6个月后,试验组患儿的尿红细胞数显著减少,效果优于对照组(P<0.05),在安全性评估方面,试验组患儿在治疗的全过程中,其转氨酶、血白细胞以及血小板数量均保持在正常范围内。结论:来氟米特在治疗激素耐药型HSPN具有显著的治疗效果,并且有良好的安全性。Objective:This study was conducted to investigate the efficacy and safety of leflunomide in the treatment of hormone-resistant children with purpura nephritis(HSPN).Methods:Children 69 cases with hormone-resistant HSPN admitted to the Department of Pediatrics of the First Hospital of Qiqihar from August 2018 to December 2022 were randomly divided into experimental group and control group by digital table method.The experimental group received hormone combined with leflunomide,while the control group received hormone combined with cyclophosphamide.At 6 months after treatment,the clinical efficacy and side effects of the drug were evaluated respectively in the two groups.Results:Before treatment,the 24-hour urinary protein quantitative mean of the two groups was similar,and there was no statistical difference(P>0.05).However,after 6 months of treatment,the urine red blood cell count in the experimental group was significantly reduced,and the effect was better than that in the control group(P<0.05).In terms of safety assessment,the number of transaminase,white blood cells and platelets in the experimental group remained within the normal range during the whole process of treatment.Conclusion:Leflunomide is effective in the treatment of hormone-resistant children with HSPN and has a good safety profile.

关 键 词：来氟米特 激素耐药 儿童紫癜性肾炎 疗效评估 安全性研究 

分 类 号：R453.9[医药卫生—治疗学] R249[医药卫生—临床医学]